More recently, the MIA series, especially MIA-602 and -690, have emerged as one of the most promising antagonists by binding to GHRH expressed on tumor cells, blocking GHRHR-mediated signaling pathways, and inhibiting tumor growth [7] (see ref. 67 in [7]). Here, GHRH is linked to neoplasm.